<DOC>
	<DOCNO>NCT00683124</DOCNO>
	<brief_summary>The major clinical problem patient Marfan Syndrome ( MFS ) aortic root dilation ( ARD ) , dissection rupture . Although available treatment ( beta-blockers , BBs ) improve evolution disease , protect MFS patient progression ARD dissection . A key molecule negatively influence cell growth , differentiation , survival death MFS TGFb antagonise exist drug employ clinical practice , Angiotensin II receptor blocker ( ARB ) .</brief_summary>
	<brief_title>Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation Genotyped Marfan Patients</brief_title>
	<detailed_description>Marfan Syndrome rare disease ( 1:5000 ) ( MIM # 154700 ) cause mutation Fibrillin 1 ( FBN1 ) gene . The major clinical problem aortic aneurysm risk dissection root diameter 5 cm . The investigator design clinical trial new generation Beta-Blocker Nebivolol expect effect shear stress , heart rate potential anti-stiffness benefit compare Losartan , Angiotensin receptor blocker anti TGF-beta effect , association molecule patient Marfan Syndrome . Nebivolol patent drug differs chemically , pharmacologically therapeutically BBs . Nebivolol show high selectivity ß1 receptor among currently available BBs , influence arterial stiffness agonistic effect ß2-receptors preserve arterial compliance . We expect significantly low progression Aortic Root Dilation arm Nebivolol plus Losartan vs. single drug ( primary end-point ) .The investigator expect : decrease arterial stiffness high arm treat drug solely Nebivolol Losartan ; decrease serum level active TGFb Losartan arm , drug &amp; age-dependant variation expression mutate FBN1 gene . As end-points , potential result improvement valve function , hard event &amp; delay surgical timing aortic root . The enrolment period last 12 month , overall follow-up period 4 year . An interim analysis primary outcome program month 24 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Dilatation , Pathologic</mesh_term>
	<mesh_term>Marfan Syndrome</mesh_term>
	<mesh_term>Arachnodactyly</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Diagnosis MFS : Ghent criterion genetically prove defect FBN1 gene Age : 12 month 55 year BSAadjusted aortic z score = &gt; 2 measure level sinus Valsalva baseline accord Roman 's method , absolute aortic root diameter &gt; 38mm female &gt; 40 mm male Prior aortic surgery and/or dissection Aortic root diameter level sinuses Valsalva 5 cm Planned aortic surgery within 6 month enrollment rate ARD progression &gt; 5 mm/year even pts ARD le 5 cm Clinical molecular diagnosis nonMFS connective tissue disease share feature MFS ( ShprintzenGoldberg syndrome LoeysDietz syndrome ) Unrenounceable therapeutic ( systemic hypertension , arrhythmia , ventricular dysfunction , valve regurgitation ) use drug ACE inhibitor , BBs , calciumchannel blocker Known sideeffects take ARB BB Intolerance ARB result termination therapy Intolerance BB result termination therapy Renal dysfunction ( creatinine level upper limit agerelated normal value ) Diabetes mellitus Pregnancy plan pregnancy within 48 month enrollment Technical limitation image study include poor acoustic window limit accurate measurement aortic root Asthma .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Marfan Syndrome</keyword>
	<keyword>Losartan</keyword>
	<keyword>Nebivolol</keyword>
	<keyword>Transforming Growth Factor Beta</keyword>
	<keyword>Aortic Root Dilation</keyword>
</DOC>